Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by aussyspitzon May 14, 2020 12:56pm
67 Views
Post# 31028366

RE:These 2-3 bashers (fake accounts)

RE:These 2-3 bashers (fake accounts)That is rich coming from "NewStockyJohnson" and as far as $50+ by EOY I think you better put down that crack pipe.

I think the most recent analyst nailed it on their 12 month price target of $9.20 CAD with no material news, projected delays and the suggested need for future financing all I see here is dead to deteriorating money for the rest of the year at a minimum. Delays will result in further increasing opportunity costs for shareholders.

Even when they finally submit the BLA I don't think it substantially moves the share price needle vs actually obtaining FDA approval/Partnership which looks now to be deep into 2021 at the earliest and by that time they will be hanging by the same debt rope they were in before.
<< Previous
Bullboard Posts
Next >>